Published in

Elsevier, Annals of Oncology, 5(19), p. 990-995, 2008

DOI: 10.1093/annonc/mdn014

Links

Tools

Export citation

Search in Google Scholar

Optimisation of circulating biomarkers of cell death for routine clinical use.

Journal article published in 2008 by Jeffrey Cummings, Alastair Cummings J. Ward T. Simpson K. Renehan A. Butt F. Moore D. Gietema J. Blackhall FH Ranson MR Hughes A. Dive C. Greystoke ORCID, Timothy H. Ward, Kathryn L. Simpson, Andrew G. Renehan, Fouziah Butt, David Moore, J. Gietema, Fiona H. Blackhall, Malcolm R. Ranson, Anthony Hughes, Caroline Dive
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

BACKGROUND: M30 and M65 enzyme-linked immunosorbent assays detect circulating cytokeratin 18 fragments released during caspase-dependent or total cell death, respectively, and have potential as biomarkers in epithelial cancers. While these assays have been validated, their robustness for routine clinical use is unknown. PATIENTS AND METHODS: M30 and M65 were measured in matched serum and plasma samples from 31 lung cancer patients and 18 controls. RESULTS: Time allowable between sample acquisition and processing is critical for assays in clinical use. A 4-h delay in processing at room temperature increased M30 (P